Literature DB >> 22806713

Response to a single dose of sildenafil in single-ventricle patients: an echocardiographic evaluation.

Kimberly W Jackson1, Ryan J Butts, Amy J Svenson, Tim C McQuinn, Andrew M Atz.   

Abstract

New evidence of increased phosphodiesterase-5 (PDE-5) in hypertrophied human myocardium suggests that sildenafil, a selective PDE-5 inhibitor, may improve muscle contraction and therefore improve ventricular function. The purpose of this study was to compare ventricular function as assessed by echocardiography in 10 surgically palliated single-ventricle patients at baseline and again after a single dose of sildenafil. The velocity time integral of the ventricular outflow tract was increased 2 h after sildenafil administration (p = 0.01), thus suggesting an improvement in cardiac output.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806713      PMCID: PMC3783569          DOI: 10.1007/s00246-012-0415-4

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  9 in total

Review 1.  Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence.

Authors:  Shahzad G Raja; Mark D Danton; Kenneth J MacArthur; James C Pollock
Journal:  J Cardiothorac Vasc Anesth       Date:  2006-04-05       Impact factor: 2.628

2.  Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.

Authors:  Phil Botha; Gareth Parry; John H Dark; Guy A Macgowan
Journal:  J Heart Lung Transplant       Date:  2009-05-13       Impact factor: 10.247

3.  Changing mortality in congenital heart disease.

Authors:  Paul Khairy; Raluca Ionescu-Ittu; Andrew S Mackie; Michal Abrahamowicz; Louise Pilote; Ariane J Marelli
Journal:  J Am Coll Cardiol       Date:  2010-09-28       Impact factor: 24.094

4.  Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial.

Authors:  David J Goldberg; Benjamin French; Michael G McBride; Bradley S Marino; Nicole Mirarchi; Brian D Hanna; Gil Wernovsky; Stephen M Paridon; Jack Rychik
Journal:  Circulation       Date:  2011-03-07       Impact factor: 29.690

5.  Comparison of the solubility and pharmacokinetics of sildenafil salts.

Authors:  Si-Young Jung; Youn-Gee Seo; Gun Kook Kim; Jong Soo Woo; Chul Soon Yong; Han-Gon Choi
Journal:  Arch Pharm Res       Date:  2011-05-06       Impact factor: 4.946

6.  Sildenafil in the management of the failing Fontan circulation.

Authors:  Zdenka Reinhardt; Orhan Uzun; Vinay Bhole; Victor Ofoe; Dirk Wilson; Obed Onuzo; John G C Wright; Oliver Stumper
Journal:  Cardiol Young       Date:  2010-06-02       Impact factor: 1.093

7.  Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients.

Authors:  Alessandro Giardini; Anna Balducci; Salvatore Specchia; Gaetano Gargiulo; Marco Bonvicini; Fernando Maria Picchio
Journal:  Eur Heart J       Date:  2008-06-04       Impact factor: 29.983

8.  The total cavopulmonary connection resistance: a significant impact on single ventricle hemodynamics at rest and exercise.

Authors:  Kartik S Sundareswaran; Kerem Pekkan; Lakshmi P Dasi; Kevin Whitehead; Shiva Sharma; Kirk R Kanter; Mark A Fogel; Ajit P Yoganathan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-17       Impact factor: 4.733

9.  Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.

Authors:  Jayan Nagendran; Stephen L Archer; Daniel Soliman; Vikram Gurtu; Rohit Moudgil; Alois Haromy; Chantal St Aubin; Linda Webster; Ivan M Rebeyka; David B Ross; Peter E Light; Jason R B Dyck; Evangelos D Michelakis
Journal:  Circulation       Date:  2007-07-02       Impact factor: 29.690

  9 in total
  2 in total

Review 1.  Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations.

Authors:  Anastacia M Garcia; Jonathan-Thomas Beatty; Stephanie J Nakano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-28       Impact factor: 4.733

2.  Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design.

Authors:  Pascal Amedro; Arthur Gavotto; Hamouda Abassi; Marie-Christine Picot; Stefan Matecki; Sophie Malekzadeh-Milani; Marilyne Levy; Magalie Ladouceur; Caroline Ovaert; Philippe Aldebert; Jean-Benoit Thambo; Alain Fraisse; Marc Humbert; Sarah Cohen; Alban-Elouen Baruteau; Clement Karsenty; Damien Bonnet; Sebastien Hascoet
Journal:  ESC Heart Fail       Date:  2020-03-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.